Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Goldenwell Biotech (GWLL) Profit After Tax (2019 - 2025)

Goldenwell Biotech filings provide 7 years of Profit After Tax readings, the most recent being -$7985.0 for Q3 2025.

  • On a quarterly basis, Profit After Tax rose 65.38% to -$7985.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$75118.0, a 39.83% increase, with the full-year FY2024 number at -$131498.0, down 12.05% from a year prior.
  • Profit After Tax hit -$7985.0 in Q3 2025 for Goldenwell Biotech, down from -$5220.0 in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$4584.0 in Q3 2022 to a low of -$920332.0 in Q4 2022.
  • Median Profit After Tax over the past 5 years was -$27536.0 (2024), compared with a mean of -$73585.9.
  • Biggest five-year swings in Profit After Tax: tumbled 16053.42% in 2021 and later skyrocketed 97.74% in 2023.
  • Goldenwell Biotech's Profit After Tax stood at -$29541.0 in 2021, then tumbled by 3015.44% to -$920332.0 in 2022, then skyrocketed by 97.74% to -$20799.0 in 2023, then crashed by 32.39% to -$27536.0 in 2024, then skyrocketed by 71.0% to -$7985.0 in 2025.
  • The last three reported values for Profit After Tax were -$7985.0 (Q3 2025), -$5220.0 (Q2 2025), and -$34377.0 (Q1 2025) per Business Quant data.